Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment.
about
Computational Approaches to Toll-Like Receptor 4 ModulationViperid Envenomation Wound Exudate Contributes to Increased Vascular Permeability via a DAMPs/TLR-4 Mediated Pathway.Basal-like breast cancer: molecular profiles, clinical features and survival outcomesAtractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitroLaricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3Porphyromonas gingivalis lipopolysaccharide induces over production of CC chemokine ligand 2 via toll-like receptor-4 in oral lichen planus.
P2860
Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Eritoran inhibits S100A8-media ...... g the immune microenvironment.
@en
type
label
Eritoran inhibits S100A8-media ...... g the immune microenvironment.
@en
prefLabel
Eritoran inhibits S100A8-media ...... g the immune microenvironment.
@en
P2093
P2860
P50
P356
P1433
P1476
Eritoran inhibits S100A8-media ...... ng the immune microenvironment
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2015.211
P407
P577
2015-07-13T00:00:00Z
P6179
1033958066